HCA-N Solution: Experimental Group using HCA-N Solution for the preservation of donor kidneys in renal transplantation
HTK Solution: control group using HTK Solution in kidney organ transplantation
Study summary
To verify the effectiveness and safety of the HCA-N solution in actual clinical preservation, this study intends to conduct a prospective, randomized, and positive control clinical trial. Using the classic HTK solution as a reference, the study will focus on evaluating the performance of the HCA-N solution in terms of the incidence of delayed recovery of transplant kidney function and the speed of early renal function recovery, with the aim of providing better preservation solution selection and high-level evidence-based guidance for clinical practice in kidney transplantation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
Recipients must meet all of the following criteria:
* Age 18 to 65 years (inclusive), regardless of gender.
* Diagnosed as eligible for allogeneic renal transplantation and willing to undergo allogeneic renal transplantation.
* Understand and agree to comply with the study requirements and voluntarily sign the informed consent form.
* Require renal transplantation and be first-time transplant recipients.
Donors must meet all of the following criteria:
* Donor kidney source aged 18 to 65 years (inclusive), regardless of gender.
* Donor's last serum creatinine before kidney procurement \< 2 mg/dL (177 μmol/L), and not having received hemodialysis.
Exclusion Criteria:
Recipients meeting any of the following criteria will be excluded:
* Planned for dual kidney transplantation.
* Planned for multi-organ combined transplantation.
* History of previous organ transplantation.
* Concurrent severe diseases, such as severe hepatic impairment, cardiopulmonary insufficiency, coagulation disorders, etc.
* Diagnosis of malignant tumor within 5 years prior to enrollment (except for adequately treated cervical carcinoma in situ, localized cutaneous squamous cell carcinoma, basal cell carcinoma, prostate cancer not requiring antitumor therapy, thyroid cancer, breast ductal carcinoma in situ, and urothelial carcinoma below T1 stage).
* Panel reactive antibody (PRA) \> 10%.
* Pregnant or lactating women.
* Participation in other drug or device clinical trials within 3 months prior to enrollment.
* Donors meeting any of the following criteria will be excluded:
* Donor has received renal replacement therapy (hemodialysis or continuous renal replacement therapy \[CRRT\]) prior to screening.
* Donor has infectious diseases unsuitable for transplantation.
Other requirements:
* ABO blood group system incompatibility between donor and recipient.
* Donor kidney warm ischemia time \> 10 minutes, or cold ischemia time \> 24 hours.
* Mechanical perfusion preservation required as assessed by the investigator.
* Other conditions that the investigator deems inappropriate for participation in this trial.
Primary outcome measure(s)
Percentage of subjects experiencing delayed graft function (DGF) post-transplantation. — Baseline at Days 1, 3, 7, 14, and 28 post-transplantation DGF is defined as the need for dialysis within 1 week after transplantation.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.